| HOME >> BIOLOGY >> TECHNOLOGY |
om the Takeda collaboration.
Interest income decreased to $679,457 for the year ended November 30, 2007, compared to $726,308 for the same period in fiscal 2006. For the three-month period ended November 30, 2007, the Company's interest income decreased to $142,329 compared to $329,342 for the same period in fiscal 2006. The decrease in interest income is the result of lower average cash and investment balances.
Research and development costs amounted to $8,606,344 for the year ended November 30, 2007, compared to $5,688,029 for the same period in fiscal 2006. For the three-month period ended November 30, 2007, the Company's research and development costs amounted to $2,144,353 compared to $2,512,366 for the same period in fiscal 2006. For the year, this increase is primarily the result of increased product development activity, including process development and scale-up, as the Company prepares several of its programs for the clinic as well as an increase in staffing levels and stock option remuneration expense. For the three month period, the decrease in research and development costs is primarily the result of decreased stock option remuneration expense and a decrease in legal expense for patents, offset by an increase in staffing levels.
General and administrative expenses increased to $3,257,430 for the
year ended November 30, 2007, compared to $2,833,802 for the same period in
fiscal 2006. For the three-month period ended November 30, 2007, the
Company's general and administrative expenses decreased to $691,910
compared to $806,589 for the same period in fiscal 2006. The increase for
the year is the result of increased head count, stock option remuneration
expense, and severance costs, partially offset by decreased consulting and
legal costs. The decrease for the three month period is the result of a
decrease in stock option remuneration expense, professional fees and
salaries, partially offset by an increase in consulting and directors fe
'/>"/>
| SOURCE ARIUS Research Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
2. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
3. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
4. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
5. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
6. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
7. ARIUS to present at Chinese Global Financial Forum
8. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
9. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
10. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
11. China Bionanometer Industries Corporation Announces Record Second Quarter 2007 Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |